Cyclerion Therapeutics Inc (CYCN)

Dec 17, 2024, 8:08 AM EST - 4 weeks ago

Cyclerion's sGC Stimulator Portfolio Generates Revenues to Enable Company Growth

Aug 7, 2024, 7:00 AM EDT - 5 months ago

Regina Graul, Ph.D., Promoted to Chief Executive Officer

Dec 4, 2023, 8:00 AM EST - 1 year ago

Cyclerion Appoints Regina Graul, Ph.D., as President

Nov 30, 2023, 6:16 PM EST - 1 year ago

Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator

Jul 31, 2023, 7:00 AM EDT - 1 year ago

Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets

Jun 1, 2023, 4:00 PM EDT - 1 year ago

Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement

May 15, 2023, 1:00 PM EDT - 1 year ago

Cyclerion Announces Reverse Stock Split

May 11, 2023, 6:00 PM EDT - 1 year ago

Cyclerion Announces Definitive Agreement for Zagociguat and CY3018

May 11, 2023, 6:00 PM EDT - 1 year ago

Cyclerion Announces Corporate Updates and Q1 2023 Financial Results

Apr 3, 2023, 7:30 AM EDT - 1 year ago

Cyclerion Therapeutics Enters into Exclusive Negotiation Period and Binding Equity Investment Agreement

Mar 27, 2023, 7:00 AM EDT - 1 year ago

Cyclerion Therapeutics Receives U.S. FDA Orphan Drug Designation for Zagociguat for the Treatment of Mitochondrial Diseases

Mar 22, 2023, 4:40 PM EDT - 1 year ago

Cyclerion Reports Corporate Update and Full Year 2022 Financial Results

Nov 22, 2022, 7:00 AM EST - 2 years ago

Cyclerion Concludes Unsolicited Proposal Is Not in The Best Interest of The Company

Oct 6, 2022, 8:00 AM EDT - 2 years ago

Cyclerion Announces Mitochondrial Disease-Focused Corporate Strategy

Aug 9, 2022, 4:00 PM EDT - 2 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and Second Quarter 2022 Financial Results

Jul 28, 2022, 7:00 AM EDT - 2 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in Patients with Cognitive Impairment Associated with Schizophrenia (CIAS)

Jul 26, 2022, 7:00 AM EDT - 2 years ago

Steven E. Hyman, M.D., Appointed to Cyclerion Therapeutics' Board of Directors

Jun 28, 2022, 9:00 AM EDT - 2 years ago

Cyclerion Therapeutics Provides Additional Positive CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 22, 2022, 8:30 AM EDT - 2 years ago

Cyclerion Therapeutics to Discuss CY6463 MELAS Clinical Data at a Webinar Hosted by United Mitochondrial Disease Foundation

Jun 17, 2022, 11:27 AM EDT - 2 years ago

Cyclerion Neurology Candidate Shows Encouraging Action In Preclinical Studies

Jun 17, 2022, 8:00 AM EDT - 2 years ago

Cyclerion Therapeutics Announces CY6463 Data Demonstrating Improved Cellular Energetics in Preclinical Models of Mitochondrial Disease

Jun 10, 2022, 7:00 AM EDT - 2 years ago

Cyclerion Therapeutics Announces Positive Topline Clinical Data for CY6463 in MELAS Patients at UMDF Mitochondrial Medicine 2022 Symposium

Jun 6, 2022, 7:00 AM EDT - 2 years ago

Cyclerion Therapeutics to Share CY6463 MELAS Topline Study Results, CHOP to Present CY6463 Preclinical Data at UMDF Mitochondrial Medicine 2022 Symposium

May 4, 2022, 4:01 PM EDT - 2 years ago

Cyclerion Announces CY6463 Clinical Pipeline Progress and First Quarter 2022 Financial Results

Feb 24, 2022, 4:01 PM EST - 3 years ago

Cyclerion Announces CY6463 Clinical Pipeline and Corporate Updates

Feb 23, 2022, 8:00 AM EST - 3 years ago

Cyclerion Therapeutics and Ariana Pharma Announce an Artificial Intelligence-driven Precision Medicine Collaboration

Jan 26, 2022, 8:00 AM EST - 3 years ago

Cyclerion Therapeutics Announces Initiation of Patient Dosing in CY6463 Phase 2a Study in Alzheimer's Disease with Vascular Pathology

Nov 11, 2021, 5:32 PM EST - 3 years ago

Cyclerion Therapeutics to Participate in Jefferies London Healthcare Conference

Nov 9, 2021, 4:01 PM EST - 3 years ago

Cyclerion Therapeutics Reports Third Quarter 2021 Financial Results and Corporate Update

Oct 26, 2021, 4:29 PM EDT - 3 years ago

Cyclerion Therapeutics: Distressed Spinoff Developing New Medicines For CNS Disorders

Oct 20, 2021, 4:24 PM EDT - 3 years ago

Truist Bullish On This Clinical-Stage Biopharmaceutical Company With 374% Upside

Sep 22, 2021, 8:00 AM EDT - 3 years ago

Cyclerion Announces Publication of Preclinical Data Demonstrating Reduction in Neuroinflammation by Brain-Penetrant sGC Stimulator

Aug 23, 2021, 5:00 PM EDT - 3 years ago

Cyclerion Therapeutics to Present at Annual Biomarkers for Alzheimer's Disease Summit

Jul 29, 2021, 5:00 PM EDT - 3 years ago

Cyclerion Therapeutics Reports Second Quarter 2021 Financial Results and Corporate Update

Jul 22, 2021, 4:30 PM EDT - 3 years ago

Cyclerion Therapeutics to Present Clinical Trial Design for CY6463 Phase 2a Study in Participants with Alzheimer's Disease with Vascular Pathology at the Alzheimer's Association International Conference 2021 (AAIC)

Jul 9, 2021, 6:14 AM EDT - 3 years ago

Cyclerion Recruits Beacon Biosignals To Identify Disease-Relevant EEG Neurological Biomarkers

Jul 8, 2021, 7:22 PM EDT - 3 years ago

Beacon Biosignals and Cyclerion Therapeutics Announce Strategic Partnership

Jul 8, 2021, 4:30 PM EDT - 3 years ago

Cyclerion Therapeutics and Beacon Biosignals Announce Expanded Strategic Partnership

Jun 4, 2021, 10:27 AM EDT - 3 years ago

Cyclerion Out-Licenses Praliciguat to Akebia, Announces $18M Capital Raise

AKBA

Jun 4, 2021, 8:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces Global Licensing Agreement with Akebia Therapeutics for Praliciguat

Jun 4, 2021, 8:00 AM EDT - 3 years ago

Cyclerion Therapeutics Announces $18 Million Private Placement

May 27, 2021, 4:30 PM EDT - 3 years ago

Cyclerion Therapeutics Announces Publication of CY6463 Preclinical Data in Frontiers in Pharmacology

May 25, 2021, 7:00 AM EDT - 3 years ago

Cyclerion Therapeutics to Participate in Jefferies Virtual Healthcare Conference

Apr 27, 2021, 12:03 PM EDT - 4 years ago

Why Cyclerion, Sol-Gel, Aldeyra, DermTech and Bionano Genomics Are Moving Today

BNGO ALDX SLGL

Apr 27, 2021, 9:00 AM EDT - 4 years ago

Cyclerion Therapeutics Hosted Webinar to Discuss Pipeline Progress

Apr 26, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics Appoints Errol De Souza, Ph.D., to Board of Directors

Apr 21, 2021, 7:30 AM EDT - 4 years ago

Cyclerion Therapeutics to Participate in the B. Riley Neuroscience Investor Conference

Apr 20, 2021, 7:00 AM EDT - 4 years ago

Cyclerion Therapeutics to Host Pipeline Update Webinar

Mar 18, 2021, 5:00 PM EDT - 4 years ago

Cyclerion Therapeutics Announces Departure of Chief Medical Officer

Jan 25, 2021, 7:00 AM EST - 4 years ago

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards